73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: University of Washington, Institut Català d'Oncologia, Institut Paoli-Calmettes, Auckland City Hospital, Centre Eugène Marquis, Hospital General Universitario Gregorio Marañón, Hôpital Européen Georges-Pompidou, Institut Gustave Roussy, Fondation Gustave Roussy, Urology Cancer Center and GU Research Network, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Merck & Co., Inc., Rahway, NJ, USA (United States), Royal Marsden NHS Foundation Trust, Institute of Cancer Research
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Astellas Pharma US, AstraZeneca, Bayer, Merck, Novartis, Sanofi, Celgene, Meso Scale Diagnostics, Exelixis, Bayer Fund, Arog Pharmaceuticals, BeiGene, Advanced Accelerator Applications, Seagen, Astellas Pharma, PharmaMar, Ipsen, Genentech, Merck Sharp and Dohme, Pharmacyclics, Janssen Pharmaceuticals, Daiichi Sankyo Europe
OpenAlex ID: W3203178979